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Abstract: Avoiding medications in which the risks outweigh the benefits in the elderly patient 
is a challenge for physicians, and different criteria to identify inappropriate prescription (IP) 
exist to aid prescribers. Definition of IP indicators in the Italian geriatric population affected 
by cardiovascular disease and chronic comorbidities could be extremely useful for prescribers 
and could offer advantages from a public health perspective. The purpose of the present study 
was to identify IP indicators by means of a systematic literature review coupled with consensus 
criteria. A systematic search of PubMed, EMBASE, and CENTRAL databases was conducted, 
with the search structured around four themes and combining each with the Boolean operator 
“and”. The first regarded “prescriptions”, the second “adverse events”, the third “cardiovascular 
conditions”, and the last was planned to identify studies on “older people”. Two investigators 
independently reviewed titles, abstracts, full texts, and selected articles addressing IP in the 
elderly affected by cardiovascular condition using the following inclusion criteria: studies on 
people aged $65 years; studies on patients with no restriction on age but with data on subjects 
aged $65 years; and observational effectiveness studies. The database searches produced 
5,742 citations. After removing duplicates, titles and abstracts of 3,880 records were reviewed, 
and 374 full texts were retrieved that met inclusion criteria. Thus, 49 studies reporting 32 potential 
IP indicators were included in the study. IP indicators regarded mainly drug–drug interactions, 
cardio- and cerebrovascular risk, bleeding risk, and gastrointestinal risk; among them, only 19 
included at least one study that showed significant results, triggering a potential warning for a 
specific drug or class of drugs in a specific context. This systematic review demonstrates that 
both cardiovascular and non-cardiovascular drugs increase the risk of adverse drug reactions 
in older adults with cardiovascular diseases.
Keywords: inappropriate prescriptions, elderly, cardiovascular diseases, chronic diseases, 
systematic review
Introduction
The world population is aging at a rapid rate, in high- and low-income countries, 
challenging health care services from both the organizational and the economic point 
of view. Throughout the world, the number of people over 60 years doubled in the 
last century and in Europe, for example, the share of older population is expected 
to peak at up to 30% by 2050.1 Such epidemiological transition drives the pressing 
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burden of the increasing prevalence of chronic diseases in 
this age group.2 In addition to the complexities related to 
the clinical management of older people suffering from 
multiple chronic diseases, one of the challenges physicians 
are facing is the consequent complication of complex phar-
macological regimens.
Even if the potential benefits of pharmacological therapy 
are unquestionable, the hazards of negative drug-related 
outcomes often raise relevant concerns in older adults. Polyp-
harmacy increases the risk of drug–drug and drug–disease 
interactions, and age-related changes in several physiological 
characteristics, as well as the presence of chronic illnesses 
(eg, chronic kidney or liver disease), may affect drugs’ phar-
macokinetics and pharmacodynamics. Such issues potentially 
increase the risk of adverse drug reactions (ADRs) and 
explain the significant excess of morbidity, mortality rate, 
and health care costs within the older population.
In this context, what constitutes an appropriate or inap-
propriate prescription (IP) in the context of the geriatric 
population is still debated. Indeed, in order to identify 
inappropriate pharmacological prescriptions, different cri-
teria have been proposed in recent years. The best known 
are the Beers criteria,3 the Screening Tool of Older People’s 
Prescriptions (STOPP), Screening Tool to Alert to Right 
Treatment (START),4 as well as the Medication Appropri-
ateness Index (MAI),5 and the Assessing Care of Vulnerable 
Elderly (ACOVE)6 criteria. These criteria and tools are 
based on expert consensus and are not specifically tailored 
to any particular disease, even though stroke, myocardial 
infarction (MI), and other cardiovascular disorders con-
stitute the most frequently treated clinical conditions by 
physicians in Western countries. Moreover, their impact 
has not been exhaustively validated toward “hard” end 
points, and they do not comprise an accurate selection and 
validation process of drug–drug interactions in light of 
overlying comorbidities.
Thus, the definition of IP indicators for older adults 
affected by cardiovascular disease and chronic comorbidities 
could be extremely useful for the prescriber and might offer 
advantages from a public health perspective. The aim of the 
present review was to identify and suggest to the scientific 
community a list of potential indicators for older adults 
suffering from cardiovascular diseases and other chronic 
comorbidities, to be subsequently validated in an ad hoc 
selected population sample, and eventually proposed as IP 
indicators. More specifically, we identified all the studies 
reporting a suspect of drug-related harm in the context of 
multimorbid older adults suffering from cardiovascular dis-
eases and clustered them according to homogenous groups. 
Cardiovascular diseases are defined according to the World 
Health Organization as
a group of disorders of the heart and blood vessels and 
include coronary heart disease, cerebrovascular disease, 
peripheral arterial disease, rheumatic heart disease, congeni-
tal heart disease, and deep vein thrombosis and pulmonary 
embolism.60
Methods
We performed this systematic review in keeping with the 
Cochrane Handbook for Systematic Reviews and reported the 
results according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA). The protocol was 
registered a priori on PROSPERO (N CRD42017057795).
Data source and search strategy
We conducted a systematic search of PubMed, EMBASE, 
and CENTRAL databases up to October 2, 2014. A librar-
ian (ZM) structured the search on free text and MESH terms 
with regard to four different domains: “prescriptions”, 
“adverse events”, “cardiovascular conditions”, and “older 
people”.
The PubMed search was ((“Drug Prescriptions”[MeSH] 
OR “Drug Utilization”[MeSH] OR “Adverse Drug 
Reactions”[tiab] OR “adverse drug events”[tiab] OR “drug 
safety”[tiab] OR “drug-drug interactions” OR ADRs[tiab] OR 
“Drug Interactions”[MeSH] OR ((inappropriate*[tiab] OR 
incorrect*[tiab] OR excess*[tiab] OR harmful*[tiab]) AND 
(medici*[tiab] OR prescrib*[tiab] OR prescription*[tiab] OR 
drug*[tiab] OR refill*[tiab] OR claim*[tiab])) OR “Drug-Re-
lated Side Effects and Adverse Reactions”[Mesh] OR ((“drug 
induced”[tiab] OR medication*[ti] OR prescription*[tiab]) 
AND (“adverse effects” [Subheading:NoExp] OR “adverse 
effects”[tiab] OR “adverse events”[tiab] OR mortality[sh])))) 
AND (“Cardiovascular  Diseases”[Mesh:noexp] 
OR “Stroke”[MeSH] OR “Arrhythmias, Cardiac”[MeSH] 
OR “Hypertension”[MeSH] OR “Heart Diseases”[MeSH] 
O R  “ B r a i n  I s c h e m i a ” [ M e S H ]  O R  “ B r a i n 
Infarction”[MeSH] OR “Myocardial Ischemia”[MeSH] 
OR “Peripheral Arterial Disease”[MeSH] OR “Angina 
Pectoris”[MeSH] OR cardiovascular[tiab] OR “heart 
disease”[tiab] OR “heart diseases”[tiab] OR “coronary 
disease”[tiab] OR “coronary diseases”[tiab] OR “heart 
failure”[tiab] OR “cardiac failure”[tiab] OR “all cause 
mortality” OR cerebrovascular[tiab])) AND (Aged[Mesh] 
OR “old people”[tiab] OR “older people”[tiab] OR “old 
age”[tiab] OR “older age”[tiab] OR “older person”[tiab] 
OR “old person”[tiab] OR geriatric*[tiab] OR elder*[tiab] 
OR senior*[tiab]).




Inappropriate pharmacological treatment in older cardiovascular adults
Identical searches were conducted in EMBASE and 
CENTRAL databases.
study selection
Two trained investigators (NL and DLV) independently 
reviewed titles and abstracts, and excluded papers using the 
following criteria:
1. Studies published in languages other than English
2. Studies on pediatric population
3. Studies regarding exposures other than drugs
4. Studies on diseases other than cardiovascular ones (eg, 
patients with cancer without cardiovascular disease, 
with Parkinson without cardiovascular disease, and with 
diabetes without cardiovascular disease)
5. Non-outcome studies.
The same investigators independently reviewed full texts 
and selected articles addressing inappropriate prescribing in 
elderly patients affected by cardiovascular condition using 
the following inclusion criteria:
1. Studies on people aged $65 years
2. Studies on patients with no restriction of age but with 
data on subjects aged $65 years
3. Observational effectiveness studies.
We resolved disagreement by discussion and consensus 
with a third trained assessor (DLC). Additionally, we reviewed 
the reference lists of the included studies and previous reviews 
to identify additional papers that met inclusion criteria.
Data extraction and quality assessment
For each selected study, we extracted the following data: 
year of publication, study design, drugs, outcomes, country 
and setting, characteristic of the study population (eg, sample 
size, age, and gender), information on follow-up, and main 
results (ie., estimated with corresponding confidence inter-
vals for each outcome) and additional results.
Two investigators (NL and DLC) independently assessed 
the methodological quality of included studies using the 
Newcastle–Ottawa Scale (NOS)7 for case–control and cohort 
study, the scale proposed by Jadad et al for randomized con-
trolled trials,8 and the following criteria for case-crossover 
studies and self-controlled case series:
1. Clearly stated aims
2. Appropriate methods are used
3. Well constituted context of the study
4. Clearly described, valid, and reliable results
5. Clearly described analysis
6. Possible influences of the outcome are considered
7. Conclusion is linked to the aim, analysis, and interpreta-
tion of results of the study
8. Limitations on research are identified.
Results
The PRISMA flow diagram of study selection is shown in 
Figure 1. The database search produced 5,742 citations. After 
removal of duplicates, we reviewed titles and abstracts of 
3880 records, among which 374 met the inclusion criteria and 
the corresponding full texts were retrieved and reviewed. Sub-
sequently, 325 studies were removed because they did not pres-
ent analysis for patients aged $65 years (258 papers) and had 
inappropriate study design (50), or for other reasons (6 were not 
original studies, 4 were on patients without cardiovascular disease, 
2 with no safety outcomes, 2 with efficacy outcomes only, 2 were 
duplicate publications, and 1 was on exposure other than drug).
Supplementary material reports the characteristics of the 
49 selected studies grouped according to 32 homogeneous 








Figure 1 PRISMA flow diagram.





two investigated bisphosphonates; seven investigated statins 
alone or in combination with ezetimibe and their interactions 
with other pharmacological agents (clopidogrel, vitamin K 
antagonists, and macrolides); eight investigated antipsy-
chotics; one investigated long-acting beta-adrenoceptor 
agonist (LABAs) and long-acting anticholinergic drugs 
(LAAs); four regarded antidiabetics; one was on aspirin in 
association with clopidogrel and enoxaparin; two regarded 
anticholinergic drugs; one was on donepezil and its interac-
tions with the antibacterial clarithromycin; two regarded 
calcium channel blockers (CCBs; short-acting nifedipine) 
and their interaction with Cytochrome P450 3A4 (CYP3A4) 
inhibitors; four regarded clopidogrel and its interactions with 
proton-pump inhibitors (PPIs); three regarded nonsteroidal 
anti-inflammatory drugs (NSAID); four regarded oral antico-
agulants (OACs); one regarded postmenopausal hormones; 
one was on opioids; one investigated angiotensin-converting-
enzyme (ACE) inhibitors; four investigated antidepressants; 
one investigated cholinesterase inhibitors; one was on 
benzodiazepines and benzodiazepine-related drugs; and one 
investigated the angiotensin receptor blocker olmesartan 
alone or in combination with other antihypertensive drugs.
Among the 32 homogeneous potential IP indicators, only 
19 included at least one study that showed significant and 
direct association with adverse events (Table 1).
In greater detail, the potentially identified IP indicators 
were:
 1. Anticholinergics (No 1) were associated with cardiac 
arrhythmia, constipation, delirium, emergency visit, and 
hospitalization.
 2. Anticholinergics in cardiovascular patients (No 2) were 
associated with hospitalization. 
 3. Antidepressants (No 3) were associated with attempted sui-
cide/self-harm, epilepsy seizures, falls, fractures, hypona-
tremia, MI, mortality, stroke/transient ischaemic attack, 
upper gastrointes tinal bleeding, and ventricular arrhythmia. 
 4. Antidepressants in coronary artery disease (CAD) patients 
(No 4) were associated with cerebrovascular events. 
 5. Antidiabetics (No 5) were associated with acute MI, 
atherosclerotic vascular heart disease, congestive heart 
failure (HF), and mortality.
 6. Antidiabetics in end-stage renal disease or disabled patients 
(No 6) were associated with HF, mortality, and stroke. 
 7. Typical antipsychotics (No 7) were associated with 
cardiovascular death, cerebrovascular events, ner vous 
system disorders, non-cancer death, respiratory dis-
orders, and stroke. Atypical antipsychotics were also 
associated with mortality and MI. 
 8. Typical antipsychotics in dementia patients (No 8) were 
associated with mortality, and MI.
 9. Bisphosphonates in fracture patients (No 12) were 
associ ated with atrial fibrillation (AF). 
 10. CCBs in hypertensive patients (No 15) were associated 
with stroke.
 11. Cholinesterase inhibitors in dementia patients (No 16) 
were associated with bradycardia, hip fractures, perma-
nent pacemaker insertion, and syncope.
 12. Clopidogrel + PPIs (No 17) were associated with MI, 
major cardiovascular events, and/or all-cause mortality.
 13. LABA and LAA in chronic obstructive pulmonary dis-
ease (COPD) patients (No 19) were associate with acute 
coronary syndrome and HF. LAA were also associated 
with cardiac arrhythmia.
 14. NSAIDs (No 21) were associated with mortality follow-
ing upper gastrointestinal events, MI and cerebrovas-
cular events, stroke, acute MI or stroke, or death from 
coronary heart disease.
 15. OACs in CAD patients (No 23) were associated with 
embolic and hemorrhagic events, gastrointestinal inju-
ries, and mortality.
 16. Opioids (No 25) were associated with MI.
 17. Statins + Macrolides (No 28) were associated with acute 
kidney injury, mortality, and rhabdomyolysis.
 18. Statins in COPD patients (No 30) were associated with 
mortality.
 19. Warfarin + potentially interacting drugs (No 32) were 
associated with bleeding.
Studies had a good quality (NOS: 9 or 8/9, quality assess-
ment: 7 or 8/8, Jadad: 4/5) in 14 out of 49 cases (29%), moder-
ate (NOS: 7 or 6/9) in 30 cases (61%), and low (NOS: ,6/9) 
in 5 cases (10%).
Discussion
The present systematic review led to the selection of 
32 groups of studies indicating potential drug-related harm 
in older people with cardiovascular diseases. Among them, 
only 19 included at least one study that showed significant and 
direct association with adverse events, triggering a potential 
warning for a specific drug or class of drugs in a specific 
context. According to the authors of the present review, these 
19 groups can be deemed as potential indicators of IP in mul-
timorbid older adults affected by cardiovascular diseases.
The optimization of pharmacological therapy is an essen-
tial part of the process of care for an older person. In the 
past 20 years, several expert panels in Canada, the USA, 
and Europe have developed different sets of criteria useful 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inappropriate pharmacological treatment in older cardiovascular adults
for making quality assessments of prescribing practices 
and medication use in older adults and potentially helpful 
during the process of medication review. The most widely 
used criteria for inappropriate medications are the Beers 
criteria,3 initially developed in 1991 in the USA to target 
nursing home residents and then revised in 1997, 2003, 2012, 
and most recently in 2015. These criteria include more than 
50 medications assigned to one of three possible categories: 
those that should always be avoided, those that are potentially 
inappropriate in older adults with particular health conditions 
or syndromes, and those that should be used with caution. 
It has been shown that potentially inappropriate medications 
included in the Beers criteria are associated with poor health 
outcomes such as confusion, falls, and mortality. Another 
important set of criteria is represented by START/STOPP4 
which were first published in 2008 and last updated in 2014. 
STOPP criteria identify prescriptions that are potentially 
inappropriate to use in patients aged $65 years, while 
START criteria list drug therapies that should be considered 
where no contraindication to prescription exists in the same 
group of patients. Beers and START/STOPP criteria overlap 
in several areas, making them able to predict ADRs, but often 
with different reliability.58,59
The list of indicators provided in the present review is 
intended as a set of potential indicators of IP that need to be 
tested in the real world through a validation process based on 
tailored studies to explore health outcomes in different older 
populations and across different care settings. Eventually, 
these validation studies might lead to a structural proposal 
for a new set of criteria of IP in older adults suffering from 
multiple chronic conditions and affected by cardiovascular 
diseases. This systematic review represents the first step 
in the process of validation of new indicators, granted by 
the Italian Medicine Agency (AIFA) and carried out by the 
I-GrADE consortium.
Our list of potential indicators partially overlaps those 
proposed by the Beers and STOPP criteria. Several drugs 
highlighted in this review, including anticoagulants, anti-
platelet, blood pressure lowering medications, and many 
psychotropic drugs, are listed by at least one of the aforemen-
tioned criteria. However, this can be no more than an indirect 
comparison, considering that this review specifically focuses 
on multimorbid older people suffering from cardiovascular 
diseases. However, when the attention of such criteria is 
focused on specific conditions, the agreement intensifies. For 
example, Beers criteria include a section of recommendations 
valid in specific contexts and make the case of HF. They 
point out NSAIDs, CCBs, thiazolidinediones, cilostazol, and 
dronedarone as potentially inappropriate medications in older 
adults suffering from HF. Interestingly, three out of five of 
these drugs have been included in our list. Several selection 
criteria beyond the specific selection of a population affected 
by cardiovascular diseases, and the decision-making process 
itself, might explain these and other discrepancies.
Several drugs not recommended for the treatment of 
cardiovascular diseases (but that have a potential role in 
determining ADRs in people with heart diseases) have been 
included in our list. Some of them are proposed here for the 
first time as potentially inappropriate. For example, in the 
study from Abrahamsen et al10 bisphosphonates showed a 
possible correlation with AF in patients with an underling 
cardiac disease. This finding, considering the high prevalence 
of both osteoporosis and cardiovascular diseases in the older 
population, represents an interesting area of future research, 
especially when considering the broad set of bisphosphonates 
with different pharmacokinetics and pharmacodynamics and 
the actual possibility of replacing these drugs with com-
pounds recently developed for the treatment of osteoporosis, 
with a more favorable safety profile and good tolerance.
On the other hand, our research underlines the potential 
harm linked to drugs that have been synthesized and are 
recommended for the treatment of cardiovascular diseases. 
This is the case of statins whose toxicity, according to a 
research published in 2013 by Patel et al,40 may be exac-
erbated when co-prescripted with macrolides (especially 
clarithromycin and erythromycin). Considering the high 
frequency of use of both classes of drugs related to the 
prevalence of cardiovascular diseases in elders and the 
presence of macrolides in first-line therapy of community-
acquired pneumonia – which is in turn a main cause of 
hospitalization in patients over 65 – it is very important to 
clarify the possible effect of such a co-prescription. In fact, 
the natural decline in renal function that accompanies aging 
may exaggerate the consequences of a rhabdomyolysis with 
a dramatic increase in the frequency of acute kidney failure 
and an excess of mortality.
As in the most recent 2015 version of Beers criteria, we 
took into account some drug–disease or drug–syndrome 
interactions. Some of them are well known and have been 
extensively explored in the literature, as is the case for 
antipsychotics and dementia, while others are completely 
new (ie., antidiabetics and stage renal disease or disability), 
thus opening the way to new and interesting knowledge 
acquisitions or future research areas.
To our knowledge, the present work is the first time 
a systematic review of studies has reported any kind of 





association between drug use and ADRs in multimorbid 
older adults suffering from cardiovascular diseases. 
However, the results we report should be read keeping in 
mind some limitations. First, we did not include any study 
assessing under use of medications, and it is now clear that 
underprescribing appropriate medications can be as great 
a concern as is overprescribing. Prescribing strategies that 
seek to simply limit the overall number of drugs prescribed 
to older adults in the name of improving quality of care may 
be seriously misdirected. Second, considering the broad and 
complex spectrum of scenarios existing when it comes to 
multimorbid older adults, and the heterogeneity of studies 
present in the literature, our search strategy might have 
missed some relevant hits. However, bibliographies of the 
selected papers were scrutinized in an attempt to reduce such 
occurrence. Third, the heterogeneity of study methodolo-
gies and care settings precludes the direct translation of our 
findings in definitive criteria of IP. However, this was an a 
priori assumption that suggests the setting up and running 
of ad hoc studies aimed at validating the criteria suggested 
here. Finally, a judgment of appropriateness cannot be issued 
on the basis of an all-or-nothing principle, but we should 
consider dose-dependent appropriateness of every drug for 
every target population. In this regard, none of the possible 
indicators relates to drug dosage, and we know that drug 
doses can be a main determinant for adverse drug events. 
Moreover, older patients often present an increased volume 
of distribution and a decreased drug clearance, which can 
prolong drug half-lives and lead to increased plasma drug 
concentrations. In addition, a decline in hepatic function with 
advancing age may account for significant variability in drug 
metabolism among older adults.
Other limitations were the exclusion of studies published 
in languages other than English and a lack of risk-of-bias 
assessment while quality of reporting was assumed to be 
directly related to quality of information.
Conclusion
The correct clinical and pharmacological management of 
complex older adults requires the availability of reliable tools 
of risk stratification, outcome prediction, and appropriate-
ness of care. According to the present systematic review, 
both cardiovascular and non-cardiovascular drugs increase 
the risk of ADRs in older adults with cardiovascular dis-
eases. As part of the I-GrADE consortium, the authors of 
the present study propose a list of potential indicators of 
IP for application in the context of multimorbid older adults 
suffering from cardiovascular diseases. It is worth passing 
such potential indicators through a validation process carried 
out in the real-world older population and across different 
care settings. This is part of the commitment of I-GrADE, 
and such a process will eventually lead to the publication of 
a reliable list of indicators of IP tailored to the aforemen-
tioned population. This and other efforts by the scientific 
community are required in the near future in order to cope 
with the emergency that stems from the rapid aging of the 
world population and to eventually provide better and more 
sustainable care to older adults.
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